Sarasota Memorial Joins Clinical Trial for Patients with Genetic Risk for Heart Disease

Business

SRQ DAILY MONDAY BUSINESS EDITION

MONDAY SEP 22, 2025 |

People who experience a sudden cardiac event related to a genetic or inherited heart condition may be eligible to participate in a new clinical trial offered by Sarasota Memorial’s Kolschowsky Research and Education Institute. Led locally by SMH cardiologist and principal investigator Jeffrey Rossi, MD, the research study is evaluating whether the investigational drug dalcetrapib can reduce mortality and heart attacks in heart patients with a recent sudden cardiac event who test positive for an AA genotype, a specific genetic variant in the ADCY9 gene. Based on the results of a previous research study, these patients with the ADCY9 AA genotype may benefit from treatment with dalcetrapib in terms of a potential reduction in future cardiac events. For more information or to find out if you are eligible to participate in the local study, contact the research team at (941) 917-2225 or researchinstitute@smh.com. For information about the national trial, visit clinicaltrials.gov.